First step: testing psoriasis Pill's safety in people with kidney issues
NCT ID NCT06380153
Summary
This small, early-stage study aimed to understand how a potential new psoriasis pill, Hemay005, is processed by the body in people with different levels of kidney function. It involved 26 adults with normal, mild, or moderate kidney impairment who took a single dose. The main goal was to gather data to help doctors safely adjust the dose for future patients whose kidneys don't work as well.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital of Tongji Medical College; Huazhong University of Science and Technology
Wuhan, Hubei, China
Conditions
Explore the condition pages connected to this study.